Azelastine eye drops receive FDA approval

Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.

Key Points

Solna, Sweden-Meda has received FDA approval for azelastine eye drops in unit dose (Optivar Unit Dose), the company announced.

The substance azelastine is an antihistamine, and the eye-drop formulation is approved for treatment of allergic conjunctivitis in adults and children.

Meda is conducting a broad development program for the substance, both as eye drops and nasal spray. The azelastine eye drops sample is one part of that development.